Importantly, the ability of VEGF-D to predict for benefit from bevacizumab was supported by the independent findings of the Australian GI Cancer Trials Group, who analyzed tissue VEGF-D by immunohistochemistry using archived formalin fixed, paraffin-embedded tumor samples 15. This evidence concerns the gene VEGFD and neoplasm.